Treatment of leishmania donovani-infected hamsters with miltefosine: Analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 2, 2012, Pages 440-443

  Gupta, Reema ^a   Kushawaha, Pramod K ^a   Samant, Mukesh ^a   Jaiswal, Anil K ^a   Baharia, Rajendra K ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Immune responses; Th1 response; Th2 response

Indexed keywords

ANTIBODY; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; MILTEFOSINE; NITRIC OXIDE; NITRITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; HAMSTER; IN VITRO STUDY; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE PROLIFERATION; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIPROTOZOAL AGENTS; CELL PROLIFERATION; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; LYMPHOCYTES; NITRIC OXIDE; PHOSPHORYLCHOLINE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TH1 CELLS; TH2 CELLS;

EID: 84855857026     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr485     Document Type: Article

References (10)

1. Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 2010; 8: 919-44.
2. Wadhone P, Maiti M, Agarwal R et al. Miltefosine promotes IFN-gdominated anti-leishmanial immune response. J Immunol 2009; 182: 7146-54.
3. Berkovic D, Grunwald U, Menzel W et al. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumour cells. Eur J Cancer 1995; 31A: 2080-5.
4. Murray HW, Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 2000; 181: 795-9.
5. Constantinescu CS, Hondowicz BD, Elloso MM et al. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998; 28: 2227-33.
6. Samant M, Sahasrabuddhe AA, Singh N et al. Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani. Parasitology 2007; 134: 1175-84.
7. Garg R, Gupta SK, Tripathi P et al. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis. Vaccine 2006; 24: 2900-9.
8. Melby PC, Tryon VV, Chandrasekar B et al. Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect Immun 1998; 66: 2135-42.
9. Samant M, Gupta R, Kumari S et al. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J Immunol 2009; 183: 470-9.
10. Banerjee A, De M, Ali N. Combination therapy with paromomycinassociated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation. Antimicrob Agents Chemother 2010; 55: 1661-70.